our trial4 Jan 2022 12:30
we will get the publicity when our results come out
Multivariant Covid-19 vaccine booster shows promise, early trial data suggests
A Covid vaccine booster aimed at tackling multiple variants shows promise in inducing a comprehensive immune response, early data suggests.
The first results of a phase one trial, launched in Manchester in September 2021, reveal the jab has strong levels of neutralising antibodies.
They are similar to approved mRNA vaccines (like Pfizer/BioNTech and Moderna), but at up to a 10-fold lower dose in the first 10 individuals, the research indicates.
According to the data the vaccine was generally safe and well-tolerated.
The jab is being trialled with the anticipated involvement of 20 people aged 60 and over, who were in good health and previously received two doses of the Oxford/AstraZeneca jab.
The findings are published by US-based biotechnology company Gritstone bio, Inc. in collaboration with the University of Manchester and Manchester University NHS Foundation Trust.
From Telegraph again